SENTI BIOSCIENCES INC (SNTI)

Company Profile

Senti Biosciences, Inc. is a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 122 full-time employees. The company went IPO on 2021-05-26. The firm is developing cell and gene therapies engineered with its gene circuit platform technologies to fight challenging diseases. The firm's products include SENTI-202, SENTI-401 and SENTI-301A. The company is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow. SENTI-401 for the potential treatment of colorectal cancer (CRC) and Other Solid Tumors. SENTI-301A for the potential treatment of HCC and Other Solid Tumors. Its gene circuit platform technologies are designed to be applied in a modality-agnostic manner, with applicability to natural killer (NK) cells, T cells, tumor infiltrating lymphocytes (TILs), stem cells, including induced Pluripotent Stem Cells (iPSCs) Hematopoietic Stem Cells (HSCs), in vivo gene therapy, such as adeno associated virus, and messenger ribonucleic acid.

Company Info

SENTI BIOSCIENCES INC

2 Corporate Drive, First Floor

South San Francisco CALIFORNIA

P: 16503823281

Employees: 122

Website: http://www.sentibio.com